
    
      This study is a randomized, prospective, multi-center, efficacy study with a DES control
      group assessing the 6-month loss in FFR in patients treated with the "matrix coated
      paclitaxel-eluting PTCA-balloon catheter" SeQuentÂ® Please and commonly used DES for small
      vessel de novo and side branch lesions. 100 patients will be studied in total with two
      equivalent treatment groups DEB & DES of 50 patients each.
    
  